Table 2 Patient characteristics and time in therapeutic range in propensity score matched episodes.

From: Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis

 

Grade 0–I (n = 8)

Grade II–III (n = 8)

P-value

Male

6 (75.0%)

5 (62.5%)

1.000(a)

Age (years)

59 (18–69)

53 (19–65)

0.562(b)

Body weight (kg)

58.5 (46.2–67.8)

54.0 (45.9–81.3)

0.879(b)

Height (cm)

164.8 (152.8–174.1)

169.5 (157.4–174.6)

0.141(b)

Serum albumin (g/dL)

3.74 (3.03–3.93)

3.73 (2.95–4.28)

1.000(b)

Serum creatinine (mg/dL)

0.82 (0.49–1.39)

0.61 (0.37–0.99)

0.279(b)

BUN (mg/dL)

16.4 (11.2–27.4)

14.3 (8.3–20.1)

0.328(b)

ALT (U/L)

21 (9–37)

14 (8–52)

0.218(b)

AST (U/L)

16 (12–34)

21 (10–32)

0.437(b)

Total bilirubin (mg/dL)

0.8 (0.5–1.3)

0.6 (0.4–1.1)

0.467(b)

γ-GTP (U/L)

61 (24–285)

43 (20–111)

0.784(b)

RBC (×106/µL)

2.54 (2.32–3.51)

2.69 (1.83–4.40)

0.959(b)

Hemoglobin (g/dL)

8.2 (6.2–11.6)

9.3 (6.3–13.0)

0.753(b)

Hematocrit (%)

24.4 (20.0–33.7)

27.1 (18.6–37.5)

0.916(b)

Platelet (×104/µL)

119 (15–200)

91 (20–106)

0.227(b)

GVHD prophylaxis

  

1.000(a)

 Tac + MMF

1 (12.5%)

0 (0.0%)

 

 Tac + mPSL

0 (0.0%)

0 (0.0%)

 

 Tac + sMTX

6 (75.0%)

6 (75.0%)

 

 PTCY

1(12.5%)

2 (25.0%)

 

Stem cell source

  

1.000(a)

 BMT

6 (75.0%)

6 (75.0%)

 

 CBT

1 (12.5%)

0 (0.0%)

 

 PBSCT

1 (12.5%)

2 (25.0%)

 

Donor type

  

1.000(a)

 Related donor

1 (12.5%)

2 (25.0%)

 

 Unrelated donor

7 (87.5%)

6 (75.0%)

 

Number of transplants

  

0.467(a)

 1

8 (100.0%)

6 (75.0%)

 

 2

0 (0.0%)

2 (25.0%)

 

 3

0 (0.0%)

0 (0.0%)

 

 4

0 (0.0%)

0 (0.0%)

 

Intensity of conditioning regimen

  

1.000(a)

 Myeloablative

3 (37.5%)

4 (50.0%)

 

 Non-myeloablative

5 (62.5%)

4 (50.0%)

 

Number of mismatched HLA antigens

  

0.804(a)

 0

5 (62.5%)

3 (37.5%)

 

 1

1 (12.5%)

2 (25.0%)

 

 2

1 (12.5%)

2 (25.0%)

 

 3

0 (0.0%)

0 (0.0%)

 

 4

1 (12.5%)

1 (12.5%)

 

GVHD grade

  

< 0.001(a)

 Free

0 (0.0%)

0 (0.0%)

 

 I

8 (100.0%)

0 (0.0%)

 

 II

0 (0.0%)

5 (62.5%)

 

 III

0 (0.0%)

3 (37.5%)

 

GVHD organ

  

0.119(a)

 Gut

1 (12.5%)

4 (50.0%)

 

 Liver

0 (0.0%)

1 (12.5%)

 

 Skin

7 (87.5%)

3 (37.5%)

 

Onset day of GVHD

26 (14–36)

26 (15–34)

1.000(b)

Disease

  

1.000(a)

 ALD

0

0

 

 ALL

2

1

 

 AML

4

4

 

 ATL

0

1

 

 BPDCN

0

0

 

 CML

0

0

 

 CMML

0

0

 

 DLBCL

0

0

 

 ENKL

0

0

 

 FL

0

1

 

 HL

0

0

 

 LBL

0

1

 

 MDS

0

0

 

 MF

1

0

 

 MPAL

0

0

 

 PCL

0

0

 

 T-PLL

1

0

 

TTR (%)

 Over 10 ng/mL for 2 weeks

100.0 (70.0‒100.0)

80.0 (61.1‒100.0)

0.043(b)

 Over 10 ng/mL for 4 weeks

96.6 (82.6‒100.0)

79.5 (60.9‒100.0)

0.044(b)

 Over 10 ng/mL for 8 weeks

74.6 (65.7‒100.0)

68.6 (56.1‒87.7)

0.270(b)

 Over 12 ng/mL for 2 weeks

61.7 (0.0‒100.0)

62.2 (0.0‒90.0)

0.875(b)

 Over 12 ng/mL for 4 weeks

69.0 (29.3‒82.6)

59.8 (43.5‒81.0)

0.461(b)

 Over 12 ng/mL for 8 weeks

55.3 (23.7‒86.8)

43.6 (33.3‒71.9)

0.442(b)

  1. Median (minimum-maximum) or n (%).
  2. BUN blood urea nitrogen, ALT alanine aminotransferase, AST aspartate aminotransferase, γ-GTP gamma-glutamyl transpeptidase, RBC red blood cell, GVHD graft-versus-host disease, MMF mycophenolate mofetil, mPSL methylprednisolone, sMTX short-term methotrexate, PTCY posttransplant cyclophosphamide, BMT bone marrow transplant, CBT cord blood transplantation, PBSCT peripheral blood stem cell transplantation, HLA human leukocyte antigen, ALD adrenoleukodystrophy, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, ATL adult T-cell leukemia/lymphoma, BPDCN blastic plasmacytoid dendritic cell neoplasm, CML chronic myeloid leukemia, CMML chronic myelomonocytic leukemia, DLBCL diffuse large B-cell lymphoma, ENKL extranodal NK/T-cell lymphoma, FL follicular lymphoma, HL Hodgkin lymphoma, LBL lymphoblastic lymphoma, MDS myelodysplastic syndromes, MF myelofibrosis, MPAL mixed phenotype acute leukemia, PCL plasma cell leukemia, T-PLL T-cell prolymphocytic leukemia, TTR time in therapeutic range.
  3. (a)Fisher’s exact test.
  4. (b)Mann–Whitney U test.
Back to article page